Hôpital Simone Veil de Blois

Research site

France Mail Pierre Charlot, 41016 Blois, France

Squamous cell carcinoma of head and neck · Breast cancer metastatic
Adult patients

About Specializations

Hôpital Simone Veil de Blois in Blois, France specialises in clinical trials of conditions such as Squamous cell carcinoma of head and neck, Breast cancer metastatic, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Mail Pierre Charlot41016 BloisFrance

Open in maps ↗

Recruiting now: no trials
Conditions studied: 2

More sites in Blois France

All trials

Ongoing trials

Clinical trials registered at this site – none is enrolling right now.

Quick filters

3 clinical trials

Squamous cell carcinoma of head and neck

Not recruiting

Study on the Safety and Tolerance of Durvalumab and Radiotherapy for Patients with Untreated Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo

Study on the Safety and Tolerance of Durvalumab and Radiotherapy for Patients with Untreated Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Durvalumab
Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Contact Research Centre

Squamous cell carcinoma of head and neck

Not recruiting

Study on Adding Nivolumab to Cisplatin and Radiotherapy for High-Risk Patients with Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo

Study on Adding Nivolumab to Cisplatin and Radiotherapy for High-Risk Patients with Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cisplatin
Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Contact Research Centre

Breast cancer metastatic

Not recruiting

Study on Alpelisib and Fulvestrant or Ribociclib and Fulvestrant for Patients with HR+, HER2- Metastatic Breast Cancer with PIK3CA Mutations

Registered drugNo placebo

Study on Alpelisib and Fulvestrant or Ribociclib and Fulvestrant for Patients with HR+, HER2- Metastatic Breast Cancer with PIK3CA Mutations

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Alpelisib
Sponsor:Unicancer

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites